AVTX

Conviction 47HealthcareScan · Thu, Sep 24, 2026

Avalo Therapeutics, Inc. (AVTX) closed at $15.70 (+2.61%) on Sep 24, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 36, RS Rating 85, -31.4% from its 52-week high, -7.8% year to date. Sector: Healthcare · PHARMACEUTICAL PREPARATIONS.

AVTX$15.70+2.61%

ResistanceSupportVol 14Insider sell

Vol MA14 1.41M

Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24

Avalo Therapeutics, Inc.PHARMACEUTICAL PREPARATIONSwww.avalotx.com ↗

Price15.70

Change+2.61%

Gap-0.20%

Rel volume4.31×

Avg volume1.22M

Avg $ vol20.87M

SMA 2017.62

SMA 5018.53

SMA 20016.85

Price vs 50-15.29%

Price vs 200-6.82%

MA stackmixed

50/200 cross—

Supertrenddown · 18.44

RSI (14)36

MACD hist-0.20

MACD cross—

Stoch %K / %D18 / 14

ADX (14)25

+DI / −DI12 / 33

RSI divergence—

MACD divergence—

ATR %6.60%

ADR %5.61%

52w high22.87

52w low10.80

From 52w high-31.35%

Above 52w low+45.37%

New 52w highNo

SqueezeOff

Bollinger width35.54%

%B0.19

Donchian pos17.74%

Donchian high20.57

Donchian low14.65

AVWAP (52w high)17.67

vs AVWAP high-11.14%

AVWAP (52w low)17.28

vs AVWAP low-9.13%

OBV trendFlat

Chaikin MF (20)-0.19

Today vs 20d4.31×

Avg vol (14d)1.41M

Avg vol (20d)1.22M

Avg $ vol (20d)20.87M

Market cap841.99M

RS Rating85 / 99

RS 3m (vs SPY)-17.27%

RS 6m (vs SPY)-4.27%

RS line new highNo

Trend template4/8

Technical rank35.0

1 week-5.93%

1 month-20.47%

3 months-12.78%

6 months+12.54%

1 year+39.56%

YTD-7.76%

P/E-10.76

P/B1.88

P/S—

P/FCF-16.33

EPS-5.84

Div yield—

ROE-17.44%

ROA-15.95%

Debt/Eq0.03

Current19.31

EV/EBITDA-10.64

Gross margin—

Net margin—

Rev growth-86.62%

EPS growth-122.78%

Price target41.80

Target upside166.24%

Analyst ratingBuy

Institutional134.90%

Ent. value771.91M

Revenue0

Net income-36.36M

Gross profit—

Free cash flow-51.55M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out52.57M

Employees33

ListedFri, Nov 13, 2015

Free float21.22M

Float %86.6%

Short interest12.39M

Days to cover15.2d

Short volume49.7%

Squeeze score86 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.83 vs −$0.66

Last surprise-25.8% miss

Setup gradeC

Conviction47 / 100

Pattern quality—

Tech rank35.0 / 100

Group rank59 / 100

Status laneNo active setup

Setup direction—

Pattern family

Resistance20.98

Support16.52

Days since event—

Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in AVTX

All disclosures →

No recent disclosed trades by Congress in AVTX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in AVTX · open-market 4 sells

Insider	Side	Shares	Value	Traded	Filed
Sullivan Christopher Ryan Chief Financial Officer · Common Stock · 2026-09-10	Sell	10.19K	$179K	2026-09-10	2026-09-11
Sullivan Christopher Ryan Chief Financial Officer · Stock Option (Right to Buy) · 2026-09-10	Exercise	10.19K	—	2026-09-10	2026-09-11
Sullivan Christopher Ryan Chief Financial Officer · Common Stock · 2026-09-10	Exercise	10.19K	$82K	2026-09-10	2026-09-11
Doyle Mittie Chief Medical Officer · Common Stock · 2026-08-28	Exercise	679	$5K	2026-08-28	2026-09-01
Doyle Mittie Chief Medical Officer · Common Stock · 2026-08-28	Sell	679	$14K	2026-08-28	2026-09-01
Doyle Mittie Chief Medical Officer · Stock Option (Right to Buy) · 2026-08-28	Exercise	679	—	2026-08-28	2026-09-01
Sullivan Christopher Ryan Chief Financial Officer · Common Stock · 2026-08-18	Sell	31.03K	$622K	2026-08-18	2026-08-19
Sullivan Christopher Ryan Chief Financial Officer · Common Stock · 2026-08-18	Exercise	31.03K	$307K	2026-08-18	2026-08-19
Sullivan Christopher Ryan Chief Financial Officer · Stock Option (Right to Buy) · 2026-08-18	Exercise	31.03K	—	2026-08-18	2026-08-19
Sullivan Christopher Ryan Chief Financial Officer · Common Stock · 2026-08-17	Sell	3.75K	$75K	2026-08-17	2026-08-19

SEC filings

EDGAR filings in AVTX · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.